On the 27th of June, we organized the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts dived into the following topics:Is the MASLD nomeclature...
On December 12th, we organised the webinar:Revolutionizing Kidney Failure Treatment: Clinical Impact and Lessons Learned from the CONVINCE Clinical TrialDuring this webinar, our speaker and hosts explored the following topics:Study d...
On the 19th of September, we presented the 9th webinar of our NASH Webinar Series. During this webinar, speaker Professor Zelber-Sagi explored the relationship between diet and NAFLD, emphasizing that diet not only causes NAFLD but can also serve ...
On May 23, we presented the webinar: Why NASH trials frequently fail and how to improve themGuest speaker: Professor Manuel Castro Cabezas Host: Professor Diederick E. GrobbeeFill in the form and watch the replay: ...
During the 5th Global NASH Congress in London, Our Chief Scientific Officer Prof. Dr. D.E. Grobbee was one of the speakers and presented: Getting GRIP on NASH; Implementation of an International Clinical Screening Program.During this presentat...
In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...
Topics that has been discussed:The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...
Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...
During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...
This webinar focussed on the close multilevel links between insulin resistance/T2DM and NAFLD.Topics that are discussed:Epidemiological links between NAFLD, insulin resistance and T2DM Insulin resistance as root cause of NAFLD: mechan...
"*" indicates required fields
"*" indicates required fields
